Zirconium-89 Oxine, for shipment 7/27/26, for delivery 7/28/26

The University of Virginia awarded a contract to 3D Imaging Drug Design & Development on July 24, 2026, for the supply and delivery of specialized pharmaceutical materials. The prime contractor is responsible for providing Zirconium-89 Oxine, a radiopharmaceutical compound, with a scheduled shipment date of July 27, 2026, and delivery on July 28, 2026. The delivery recipient is identified as Natasha Diba Sheybani. The contract is valued at $2,750.00 for a single unit of material.

This procurement represents a minimal-value transaction typical of routine supply acquisitions within Virginia's academic research sector. The University of Virginia, serving as the contracting organization, engaged 3D Imaging Drug Design & Development as the prime contractor for this specialized chemical compound essential to pharmaceutical research and development operations. The compressed performance schedule—spanning three calendar days from award through delivery—indicates an urgent fulfillment requirement aligned with the institution's research timelines and operational needs.